#USA #San Mateo #Rare Disease #Astrosalva Therapeutics #Wendy Erler

Enhancing Patient Advocacy in Biotechnology: Wendy Erler at Astrosalva Therapeutics

Astrosalva Therapeutics, a preclinical biotechnology firm focused on developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), has welcomed Wendy Erler to its Strategic Advisory Board. This appointment signifies a commitment to incorporating patient advocacy into the company's strategies and operations.

Wendy Erler, who currently serves as Senior Vice President of Patient Affairs at Sarepta Therapeutics, brings over two decades of valuable experience in patient advocacy, rare disease strategy, and medical affairs. Her extensive background will play a pivotal role in shaping Astrosalva's approach to engaging with patients and their families.

At Astrosalva, Erler will spearhead initiatives designed to enhance patient and community engagement. This includes working with existing natural history registries and ensuring that patient and caregiver perspectives inform the planning of upcoming clinical trials. Erler emphasizes the importance of considering patient engagement as a foundational element in drug development rather than a mere afterthought.

Paul Schmidt, co-founder and CEO of Astrosalva, expressed confidence in Erler’s appointment, stating, "Wendy is the first advisor we are announcing, and that order is deliberate. We want families to know from the start that we are building this company around patients and their communities, alongside great science." He underlined the need for a patient-centered approach in the biopharmaceutical industry, particularly when addressing rare diseases like Alexander disease.

Erler shares this vision, reinforcing that patient engagement must be integrated deeply within how a company operates. She stated, "I'm excited to join Astrosalva's Strategic Advisory Board at such an important stage early in the company's journey. There is a meaningful opportunity to build on the knowledge and experiences of the Alexander disease and ALD communities. Ultimately, the goal is to ensure that the science we advance is informed by what matters most to the people and families waiting for new treatments."

Astrosalva’s mission is clear: prioritize the insights and experiences of patients and their families in all aspects of drug development. This approach sets a new standard within the industry, advocating for a model that prioritizes patient needs from the very beginning of the drug development process.

Founded by Thomas Wagner and Paul Schmidt, Astrosalva Therapeutics is dedicated to tackling the challenges of Alexander disease and cALD through innovation and collaboration with the patient community. Although still in the preclinical stages, the company is positioned for significant impact as it moves toward potential clinical trials. The leadership team is experienced, with Paul Schmidt having spent nearly 15 years in the biopharma industry, over ten of which have been focused on rare diseases.

In addition to her role at Astrosalva, Erler has also held significant positions at Alexion, where she led the Global Patient Experience function, developing a comprehensive model to incorporate patient insights into business operations. She has initiated patient advocacy programs at various organizations, such as Wave Life Sciences and has served on boards for organizations like Global Genes / RARE-X and Odylia Therapeutics.

Families, clinicians, and patient advocacy organizations interested in learning more about Astrosalva Therapeutics or becoming involved can reach out via their official email or visit the company’s website for updates. They will also have the opportunity to meet with Astrosalva at the upcoming 2026 ALD Connect Annual Meeting and Patient Learning Academy scheduled for November 6-7.

In conclusion, with Wendy Erler on board, Astrosalva Therapeutics is poised to advance its mission of patient-centered drug development, promising hope for those affected by Alexander disease and cALD. This strategic move highlights the increasing importance of integrating patient voices into the life sciences narrative, fostering a culture of transparency and community engagement that ultimately drives better health outcomes.